OncoPep
0 followers
Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell-focused technologies are designed to be used on their own or in combination with other immunotherapeutics.
Org chart
Arthur Becker
Collapse
Victor Moyo
Chief Medical Officer
Sobin Kim
Chief Technology Officer
Doris Peterkin
Head, Vaccine Development
Tina Soulis
Director, Australia
Jennifer Bukoff
Quality Systems Controller
